The role and efficacy of Obinutuzumab

Obinutuzumab is used to treat or slow the progression of chronic lymphocytic leukemia and follicular lymphoma. It targets a specific antigen called CD20 on normal and cancerous B lymphocytes, which signals the immune system to attack and destroy these cells. Stem cells are not affected because they do not have this antigen.

Otuzumab is a monoclonal antibody, which is a man-made protein that works similarly to human antibodies in the immune system. They are a type of "targeted" cancer treatment, but are usually only used in cancers for which the antigen (and its specific antibody) has been identified. Otuzumab targets a specific antigen called CD20, a protein found on normal and cancerous B lymphocytes. Otuzumab binds to this protein, which signals cells in our immune system to attack and kill labeled B cells. This occurs through several different mechanisms, such as activation of signaling pathways that trigger cell death. While otuzumab causes cell death in normal and malignant B cells, stem cells, the young cells in the bone marrow that develop into various cell types, do not have the CD20 antigen and are not vulnerable to attack.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.